Literature DB >> 27461013

[Surgical removal of Salzmann's nodules using intraoperative mitomycin C].

D Böhringer1, D Widmer2, P Eberwein2, P Maier2, T Reinhard2.   

Abstract

Salzmann's nodules comprise a heterogeneous group of greyish superficial corneal opacities. A substantial percentage is most likely caused by dystrophies. This could explain the recurrences after surgical removal. The Eye Center of the University Hospital Freiburg has been using mitomycin C intraoperatively during surgical removal of Salzmann's nodules since 2007 to prevent recurrences. We recently performed an uncontrolled prospective trial to evaluate this approach and also reviewed the literature. Worldwide, a total of 38 eyes have been treated with mitomycin C during surgery for Salzmann's nodules. No recurrences have been reported so far with follow-up exceeding at least 2 years in almost all eyes. No severe side effects have been observed to date. We therefore think that mitomycin C during surgery for Salzmann's nodules is advisable despite the lack of evidence from a randomized clinical trial. However, all patients must consent to the off label use of mitomycin C.

Entities:  

Keywords:  Corneal degeneration; Dystrophy; Off label use; Prevention; Recurrence

Mesh:

Substances:

Year:  2016        PMID: 27461013     DOI: 10.1007/s00347-016-0335-4

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  12 in total

1.  Long-term outcome of excimer laser phototherapeutic keratectomy for treatment of Salzmann's nodular degeneration.

Authors:  Sujata Das; Achim Langenbucher; Pavel Pogorelov; Barbara Link; Berthold Seitz
Journal:  J Cataract Refract Surg       Date:  2005-07       Impact factor: 3.351

2.  Meta-analysis on the recurrence rates after bare sclera resection with and without mitomycin C use and conjunctival autograft placement in surgery for primary pterygium.

Authors:  J C Sánchez-Thorin; G Rocha; J B Yelin
Journal:  Br J Ophthalmol       Date:  1998-06       Impact factor: 4.638

3.  Re: peripheral hypertrophic subepithelial corneal degeneration - clinical and histopathological features.

Authors:  Madalina-Adriana Chihaia; Daniel Böhringer; Philipp Eberwein; Thomas Reinhard
Journal:  Acta Ophthalmol       Date:  2015-03-23       Impact factor: 3.761

4.  Excimer laser phototherapeutic keratectomy retreatment of anterior basement membrane dystrophy and Salzmann's nodular degeneration with topical mitomycin C.

Authors:  Alexandre S Marcon; Christopher J Rapuano
Journal:  Cornea       Date:  2002-11       Impact factor: 2.651

5.  Peripheral hypertrophic subepithelial corneal degeneration presenting with bilateral nasal and temporal corneal changes.

Authors:  M Schargus; C Kusserow; U Schlötzer-Schrehardt; C Hofmann-Rummelt; G Schlunck; G Geerling
Journal:  Eye (Lond)       Date:  2014-10-03       Impact factor: 3.775

6.  Epithelial marker expression in Salzmann nodular degeneration shows characteristics of limbal transient amplifying cells and alludes to an involvement of the epithelium in its pathogenesis.

Authors:  Philipp Eberwein; Sonja Hiss; Claudia Auw-Haedrich; Rainer Sundmacher; Katharina Hauer; Daniel Boehringer; Peter Meier; Thomas Reinhard
Journal:  Acta Ophthalmol       Date:  2010-06-25       Impact factor: 3.761

Review 7.  Salzmann's nodular degeneration of the cornea: a review and case series.

Authors:  Sujata Das; Barbara Link; Berthold Seitz
Journal:  Cornea       Date:  2005-10       Impact factor: 2.651

8.  Superficial keratectomy, PTK, and mitomycin C as a combined treatment option for Salzmann's nodular degeneration: a follow-up of eight eyes.

Authors:  Riad Khaireddin; Toam Katz; Rahul B Baile; Gisbert Richard; Stephan J Linke
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-05       Impact factor: 3.117

9.  [Salzmann's nodular degeneration. Mostly an epithelial corneal dystrophy].

Authors:  R Sundmacher
Journal:  Ophthalmologe       Date:  2012-04       Impact factor: 1.059

10.  Peripheral hypertrophic subepithelial corneal degeneration - clinical and histopathological features.

Authors:  Petri J Järventausta; Timo M T Tervo; Tero Kivelä; Juha M Holopainen
Journal:  Acta Ophthalmol       Date:  2014-03-21       Impact factor: 3.761

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.